Techno Medica Co., Ltd.
Stock Price Chart
2026/08/05 UpdatedPrice Trend
2026/08/05 UpdatedPrice & Trading Details
2026/08/05 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History 1Years Growth
Updated 2026/08/02| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥129 | +89.7% |
| 2025 | ¥68 | 0.0% |
| 2024 | ¥68 | +13.3% |
| 2023 | ¥60 | 0.0% |
| 2022 | ¥60 | - |
Financial Performance
2026/08/02 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥9,368M | ¥10,284M | ¥9,906M | ¥11,237M |
| Gross Profit | ¥4,630M | ¥5,152M | ¥4,928M | ¥5,243M |
| Operating Income | ¥1,649M | ¥1,840M | ¥1,300M | ¥1,668M |
| Pretax Income | ¥1,649M | ¥1,840M | ¥1,300M | ¥1,668M |
| Net Income | ¥1,151M | ¥1,348M | ¥1,005M | ¥1,071M |
| EPS | ¥136.35 | ¥172.95 | ¥145.08 | - |
| Operating Margin | 17.61% | 17.89% | 13.13% | 14.85% |
| Balance Sheet | ||||
| Total Assets | ¥19,443M | ¥17,434M | ¥17,939M | ¥17,966M |
| Total Equity | ¥16,387M | ¥13,819M | ¥14,389M | ¥14,410M |
| Total Liabilities | ¥3,056M | ¥3,615M | ¥3,550M | ¥3,556M |
| Cash | ¥11,750M | ¥8,586M | ¥9,061M | ¥8,976M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 84.28% | 79.26% | 80.21% | 80.21% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥887M | ¥1,143M | ¥978M | ¥1,100M |
| Investing CF | -¥155M | -¥101M | -¥32M | -¥40M |
| Financing CF | -¥505M | -¥4,206M | -¥470M | -¥1,146M |
| Free CF | ¥749M | ¥1,040M | ¥946M | ¥1,059M |
| Efficiency | ||||
| ROE | 7.02% | 9.76% | 6.98% | 7.43% |
| ROA | 5.92% | 7.73% | 5.60% | 5.96% |
Latest IR Information
-
First Quarter Financial Summary for the Fiscal Year Ending March 2027 (Japanese GAAP) (Consolidated)
Sales growth driven by blood collection tube preparation devices. First quarter net sales were 2.2022 billion yen, up 25.3% YoY; quarterly net income rose significantly to 1.599 billion yen. Full-year guidance has been revised; the second quarter outlook includes upward...
Read more -
Notice regarding the Revision of Earnings Guidance for the Second Quarter of the Fiscal Year Ending March 2027
Earnings guidance for the second quarter of the fiscal year ending March 2027 has been revised upward. Revenue 4,360 million yen from 4,270 million yen, operating income 300 million yen from 170 million yen, ordinary income 310 million yen from...
Read more -
Completion of Share Buyback｜July 2026
TechnoMedica Corporation completed the disposal of 19,800 shares of treasury stock at 1,968 yen per share on July 24, 2026, raising a total of 38,966,400 yen. The disposal was allocated to four directors.
Read more -
Notice Regarding Disposition of Treasury Stock as Stock-Based Compensation
Read more
Latest News (5 items)
Company Information
About
Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers automated tube selecting and labeling systems, RFID process control system, blood and urine collection support, and pre-analytical instrument. It also provides consumables and after sales services. Techno Medica Co., Ltd. was incorporated in 1987 and is headquartered in Yokohama, Japan.
